Drug
Ribupatide clinical trials
Also written HRS9531 and KAI-9531.
- studies test it
- 32
- open now
- 9
- in phase 3
- 12
- first study started
- 2021
Keep track of what changes. Save the ribupatide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
32 studies that test it; most in 2024 (11)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 11 |
| 2025 | 8 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 9
- Phase 3
- 12
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 31 · Other 1
Fujian Shengdi Pharmaceutical Co., Ltd. (26) · Kailera (5) · Shanghai Zhongshan Hospital (1)
Often tested with
Tested in the same studies.
HRS-4729 (2) · Metformin (2) · Acetaminophen (1) · Warfarin (1) · Atorvastatin (1) · Digoxin (1)
Studies
Open first, then newest update. How each study uses ribupatide is read from its arms, and is right about nine times in ten.
Testing it · 32
- A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of RibupatideRecruitingPhase 1KaileraNCT07793929Written as Ribupatide
- A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular DiseaseRecruitingPhase 3Fujian Shengdi Pharmaceutical Co., Ltd.NCT07551492Written as HRS9531
- A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated SteatohepatitisRecruitingPhase 2Fujian Shengdi Pharmaceutical Co., Ltd.NCT07660848Written as HRS9531 Injection
- A Trial of Ribupatide Injection in Participants With Obesity and Knee OsteoarthritisNot yet recruitingPhase 3Fujian Shengdi Pharmaceutical Co., Ltd.NCT07709910Written as Ribupatide Injection
- A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic FunctionRecruitingPhase 1Fujian Shengdi Pharmaceutical Co., Ltd.NCT07540754Written as HRS9531 Injection
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) TherapyRecruitingPhase 3Fujian Shengdi Pharmaceutical Co., Ltd.NCT06994650Written as HRS9531
- Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal InsulinRecruitingPhase 3Fujian Shengdi Pharmaceutical Co., Ltd.NCT07060456Written as HRS9531
- A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and ObesityRecruitingPhase 3Fujian Shengdi Pharmaceutical Co., Ltd.NCT06974851Written as HRS9531
- A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep ApneaNot yet recruitingPhase 2Fujian Shengdi Pharmaceutical Co., Ltd.NCT06565871Written as HRS9531 Injection
- A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without DiabetesCompletedPhase 2Fujian Shengdi Pharmaceutical Co., Ltd.NCT05881837Written as HRS9531 injection
- Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesActive, not recruitingPhase 3KaileraNCT07284901Written as Ribupatide
- Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesActive, not recruitingPhase 3KaileraNCT07284979Written as Ribupatide
- Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesActive, not recruitingPhase 3KaileraNCT07284875Written as Ribupatide
- A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 DiabetesCompletedPhase 3Fujian Shengdi Pharmaceutical Co., Ltd.NCT06649344Written as HRS9531 Injection
- Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have DiabetesActive, not recruitingPhase 2KaileraNCT07458269Written as Ribupatide
- the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise AloneCompletedPhase 3Fujian Shengdi Pharmaceutical Co., Ltd.NCT06650007Written as HRS9531 Injection
- Efficacy and Safety of HRS9531 Injections in Overweight or Obese SubjectsCompletedPhase 2Fujian Shengdi Pharmaceutical Co., Ltd.NCT06054698Written as HRS9531 injection
- A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy SubjectsCompletedPhase 1Fujian Shengdi Pharmaceutical Co., Ltd.NCT06246175Written as HRS9531
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy SubjectsCompletedPhase 1Fujian Shengdi Pharmaceutical Co., Ltd.NCT06762600Written as HRS9531 injection
- A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With ObesityActive, not recruitingPhase 3Fujian Shengdi Pharmaceutical Co., Ltd.NCT07285902Written as HRS9531 injection
Codes
What other systems call ribupatide · ClinicalTrials.gg INT015036
- UNII (FDA) 58K8SFK97CRIBUPATIDEOne source FDA
- NCI Thesaurus C224785RibupatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 58K8SFK97C | RIBUPATIDE | One source FDA |
| NCI Thesaurus | C224785 | Ribupatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.